Aprea Therapeutics, Inc. (APRE)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-13) · 99.1 · 99.2 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-16) · 99.1 · 99.2 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 · 99.2 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 · 99.2 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-14) · 99.1 · 99.2 | ||
| 10-K | FY-2024 | 8-K (2025-03-25) · 99.1 · 99.2 | 8-K (2025-01-13) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 · 99.2 | 8-K (2024-10-09) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-12) · 99.1 · 99.2 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-14) · 99.1 · 99.2 | ||
| 10-K | FY-2023 | 8-K (2024-03-26) · 99.1 · 99.2 | 8-K (2024-02-02) | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 · 99.2 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-10) · 99.1 · 99.2 | ||
| 10-K/A | FY-2021 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Expenses | ||
| Acquisition of Atrin | — |
|
| Acquisition of Atrin Pharmaceuticals | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Equity Incentive Plan | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Nature of Business and Basis of Presentation | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment | — |
|
| Stock Option Plans | — |
|
| Stockholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||